| 2.5 -0.065 (-2.53%) | 07-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.67 | 1-year : | 4.4 |
| Resists | First : | 3.14 | Second : | 3.76 |
| Pivot price | 2.97  |
|||
| Supports | First : | 2.14 | Second : | 1.78 |
| MAs | MA(5) : | 2.73 |
MA(20) : | 2.94  |
| MA(100) : | 3.5 |
MA(250) : | 3.14 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8 |
D(3) : | 15.4 |
| RSI | RSI(14): 39.3 |
|||
| 52-week | High : | 9.07 | Low : | 1.08 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CNTN ] has closed above bottom band by 11.2%. Bollinger Bands are 4.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.63 - 2.64 | 2.64 - 2.65 |
| Low: | 2.41 - 2.43 | 2.43 - 2.45 |
| Close: | 2.47 - 2.5 | 2.5 - 2.53 |
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
Mon, 29 Jun 2026
Canton Strategic Holdings, Inc.(NasdaqCM:CNTN) added to Russell 2000 Value Benchmark - marketscreener.com
Thu, 25 Jun 2026
Canton Strategic Holdings, Inc. Actuals & Estimates (NASDAQ:CNTN) - TradingView
Tue, 23 Jun 2026
Canton Strategic starts lock-up service for Canton Coin users - Stock Titan
Tue, 23 Jun 2026
Canton Strategic Holdings, Inc. Announces Launch of Locking Service to Support Network Infrastructure Providers - Yahoo Finance
Thu, 18 Jun 2026
Canton Strategic Holdings expected to join Russell indexes - Investing.com
Tue, 16 Jun 2026
Canton Strategic Holdings, Inc. Announces Authorization of Share Repurchase Program - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 77 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 17.5 (%) |
| Held by Institutions | 16.5 (%) |
| Shares Short | 4,680 (K) |
| Shares Short P.Month | 3,180 (K) |
| EPS | -0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.7 % |
| Return on Equity (ttm) | -34.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -6.95 |
| PEG Ratio | 0 |
| Price to Book value | 0.3 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|